Study finds potential cognitive benefits for lupus patients using memantine
Researchers report that memantine, a drug commonly used for dementia, may help improve cognitive function in individuals with neuropsychiatric systemic lupus erythematosus.
Written automatically from the sources below and not individually reviewed by a human editor.
A recent clinical trial has shown promising results for patients with neuropsychiatric systemic lupus erythematosus (NPSLE), a condition often marked by cognitive challenges. Researchers led by Jillian Rhoads at Vanderbilt University conducted a placebo-controlled study involving individuals experiencing cognitive difficulties linked to the disease. The findings suggest that memantine, a medication typically prescribed for dementia, may offer meaningful improvements in cognitive function for this patient group. Participants using memantine reported greater subjective benefits compared to those receiving a placebo, indicating potential relief from symptoms like brain fog and memory issues. While the study highlights encouraging outcomes, further research will be needed to confirm these effects and determine optimal treatment approaches. The results could open new avenues for managing cognitive symptoms in NPSLE, offering hope for patients who currently have limited treatment options for these challenges. The trial underscores the importance of exploring repurposed medications to address unmet needs in complex autoimmune conditions.
Sources
1 sourceThe article is grounded in the independently assessed evidence listed here.
Generated from retrieved source material, checked for evidence and provenance, and released through runtime safety controls.
Read our editorial standard →Spot a problem?
Reports go to the operator review queue and do not alter the article automatically.
